To the full analysis
Bristol-Myers Squibb stock: growth
BMYBristol-Myers Squibb reported $48.2B in revenue for fiscal 2025, down 0.2% on the prior year, up 2.5% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
5.3%
per year from 2006 to 2025, per share 5.1%
Earnings (Annual rate)
8.2%
per year from 2006 to 2025, per share 7.9%
Free cash flow (Annual rate)
12.9%
per year from 2006 to 2025, per share 12.6%
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2020 | since 2015 | since 2006 | |
|---|---|---|---|
| Revenue | 2.5% | 11.3% | 5.3% |
| Revenue per share | 4.6% | 9.0% | 5.1% |
| Earnings | no data | 16.2% | 8.2% |
| Earnings per share | no data | 13.6% | 7.9% |
| Free cash flow | −0.7% | 25.9% | 12.9% |
| Free cash flow per share | 1.3% | 23.4% | 12.6% |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2006 | $17.91B | $1.59B | $1.29B |
| 2007 | $19.35B | $2.17B | $2.31B |
| 2008 | $20.6B | $5.25B | $2.77B |
| 2009 | $18.81B | $10.61B | $3.34B |
| 2010 | $19.48B | $3.1B | $4.07B |
| 2011 | $21.24B | $3.71B | $4.47B |
| 2012 | $17.62B | $1.96B | $6.39B |
| 2013 | $16.39B | $2.56B | $3.01B |
| 2014 | $15.88B | $2B | $2.62B |
| 2015 | $16.56B | $1.57B | $1.29B |
| 2016 | $19.43B | $4.46B | $1.84B |
| 2017 | $20.78B | $1.01B | $4.22B |
| 2018 | $22.56B | $4.92B | $6.12B |
| 2019 | $26.15B | $3.44B | $7.37B |
| 2020 | $42.52B | −$9.02B | $13.3B |
| 2021 | $46.39B | $6.99B | $15.23B |
| 2022 | $46.16B | $6.33B | $11.95B |
| 2023 | $45.01B | $8.03B | $12.65B |
| 2024 | $48.3B | −$8.95B | $13.94B |
| 2025 | $48.2B | $7.05B | $12.85B |
Revenue by segment
How Bristol-Myers Squibb Company makes its money and how that has shifted. Names are as the company reports them.
- Eliquis30%
- Opdivo21%
- Orencia8%
- Revlimid6%
- Yervoy6%
- Pomalyst/Imnovid6%
- Other24%
“Other” combines smaller and former segments with revenue the company does not assign to a segment. Names as reported, with abbreviations spelled out for the largest companies.
Figures as a table
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Share 2025 | |
|---|---|---|---|---|---|---|---|---|
| Eliquis | $7.93B | $9.17B | $10.76B | $11.79B | $12.21B | $13.33B | $14.44B | 30% |
| Opdivo | $7.2B | $6.99B | $7.52B | $8.25B | $9.01B | $9.3B | $10.05B | 20.9% |
| Orencia | $2.98B | $3.16B | $3.31B | $3.46B | $3.6B | $3.68B | $3.71B | 7.7% |
| Revlimid | $1.3B | $12.11B | $12.82B | $9.98B | $6.1B | $5.77B | $2.95B | 6.1% |
| Yervoy | $1.49B | $1.68B | $2.03B | $2.13B | $2.24B | $2.53B | $2.9B | 6% |
| Pomalyst/Imnovid | $322M | $3.07B | $3.33B | $3.5B | $3.44B | $3.55B | $2.73B | 5.7% |
| Other | $4.93B | $6.34B | $6.62B | $7.05B | $8.41B | $10.13B | $11.41B | 23.7% |
| Total revenue | $26.15B | $42.52B | $46.39B | $46.16B | $45.01B | $48.3B | $48.2B | 100% |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Strong since 11 Nov 2026, previously Neutral
- Valuation signal Undervalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.